# TON Strategy Co: financial statements, quarterly

TONX · Nasdaq · CIK 1566610 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tonx.md) · [Financials](/companies/tonx/financials.md) · [Filings](/companies/tonx/filings.md) · [Insiders](/companies/tonx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tonx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001493152-24-043700.md) | [0.0 d](/filings/0001641172-25-000518.md) | [0.0](/filings/0001641172-25-009842.md) | [0.0](/filings/0001493152-25-011636.md) | [0.1](/filings/0001493152-25-021741.md) | [0.7 d](/filings/0001493152-26-013931.md) | [1.3](/filings/0001493152-26-022422.md) | [2.1](/filings/0001493152-25-011636.md) | [3.6](/filings/0001493152-25-021741.md) | [5.7 d](/filings/0001493152-26-013931.md) | [5.3](/filings/0001493152-26-022422.md) | [15.0](/filings/0001493152-26-037002.md) |
| Cost of revenue | $m | [0.0](/filings/0001493152-24-043700.md) | [0.0 d](/filings/0001641172-25-000518.md) | [0.0](/filings/0001641172-25-009842.md) | [0.0](/filings/0001493152-25-011636.md) | [0.1](/filings/0001493152-25-021741.md) | [0.1 d](/filings/0001493152-26-013931.md) | [0.3](/filings/0001641172-25-009842.md) | [0.6](/filings/0001493152-25-011636.md) | [0.9](/filings/0001493152-25-021741.md) | [2.0 d](/filings/0001493152-26-013931.md) | [1.3](/filings/0001493152-26-022422.md) | [0.8](/filings/0001493152-26-037002.md) |
| Gross profit | $m | [0.0](/filings/0001493152-23-041280.md) | not reported | not reported | not reported | not reported | not reported | [0.7](/filings/0001493152-26-022422.md) | not reported | not reported | not reported | [4.0](/filings/0001493152-26-022422.md) | [14.3](/filings/0001493152-26-037002.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.4)](/filings/0001493152-24-043700.md) | [(3.0) d](/filings/0001641172-25-000518.md) | [(3.2)](/filings/0001641172-25-009842.md) | [(2.4)](/filings/0001493152-25-011636.md) | [(2.3)](/filings/0001493152-25-021741.md) | [(3.7) d](/filings/0001493152-26-013931.md) | [(2.7)](/filings/0001493152-26-022422.md) | [(1.3)](/filings/0001493152-26-037002.md) | [(21.7)](/filings/0001493152-25-021741.md) | [(9.1) d](/filings/0001493152-26-013931.md) | [(3.9)](/filings/0001493152-26-022422.md) | [0.5](/filings/0001493152-26-037002.md) |
| Interest expense | $m | [0.2](/filings/0001493152-23-041280.md) | [0.2 d](/filings/0001493152-24-012416.md) | [0.2](/filings/0001493152-24-018691.md) | [0.0](/filings/0001493152-25-011636.md) | [0.0](/filings/0001493152-25-021741.md) | [0.0 d](/filings/0001493152-26-013931.md) | [0.0](/filings/0001641172-25-009842.md) | [0.0 d](/filings/0001493152-25-011636.md) | [0.0 d](/filings/0001493152-25-021741.md) | [0.0 d](/filings/0001493152-26-013931.md) | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-26-037002.md) | [14.4](/filings/0001493152-25-021741.md) | [(14.4) d](/filings/0001493152-26-013931.md) | not reported | [0.0](/filings/0001493152-26-037002.md) |
| Net income | $m | [(3.7)](/filings/0001493152-24-043700.md) | [(2.9) d](/filings/0001641172-25-000518.md) | [(3.4)](/filings/0001641172-25-009842.md) | [(1.7)](/filings/0001493152-25-011636.md) | [(2.0)](/filings/0001493152-25-021741.md) | [(3.2) d](/filings/0001493152-26-013931.md) | [(2.6)](/filings/0001493152-26-022422.md) | [(2.4)](/filings/0001493152-26-037002.md) | [84.3](/filings/0001493152-25-021741.md) | [(228) d](/filings/0001493152-26-013931.md) | [(91.0)](/filings/0001493152-26-022422.md) | [76.8](/filings/0001493152-26-037002.md) |
| Diluted EPS | $ per share | [(130.64)](/filings/0001493152-24-043700.md) | not reported | [(22.60)](/filings/0001641172-25-009842.md) | [(3.35)](/filings/0001493152-25-011636.md) | [(3.82)](/filings/0001493152-25-021741.md) | not reported | [(2.51)](/filings/0001493152-26-022422.md) | [(1.79)](/filings/0001493152-26-037002.md) | [2.23](/filings/0001493152-25-021741.md) | not reported | [(1.56)](/filings/0001493152-26-022422.md) | [1.31](/filings/0001493152-26-037002.md) |
| Basic EPS | $ per share | [(130.64)](/filings/0001493152-24-043700.md) | not reported | [(22.60)](/filings/0001641172-25-009842.md) | [(3.35)](/filings/0001493152-25-011636.md) | [(3.82)](/filings/0001493152-25-021741.md) | not reported | [(2.51)](/filings/0001493152-26-022422.md) | [(1.79)](/filings/0001493152-26-037002.md) | [2.23](/filings/0001493152-25-021741.md) | not reported | [(1.56)](/filings/0001493152-26-022422.md) | [1.32](/filings/0001493152-26-037002.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-08-07) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.4](/filings/0001641172-25-000518.md) | [14.2](/filings/0001493152-24-018691.md) | [17.2](/filings/0001493152-24-032262.md) | [10.5](/filings/0001493152-24-043700.md) | [7.6](/filings/0001493152-26-013931.md) | [7.2](/filings/0001641172-25-009842.md) | [5.2](/filings/0001493152-25-011636.md) | [11.4](/filings/0001493152-26-037002.md) | [53.9](/filings/0001493152-25-021741.md) | [39.5](/filings/0001493152-26-037002.md) | [34.8](/filings/0001493152-26-022422.md) | [28.8](/filings/0001493152-26-037002.md) |
| Current assets | $m | [4.7](/filings/0001641172-25-000518.md) | [14.5](/filings/0001493152-24-018691.md) | [17.6](/filings/0001493152-24-032262.md) | [15.8](/filings/0001493152-24-043700.md) | [16.5](/filings/0001493152-26-013931.md) | [14.3](/filings/0001641172-25-009842.md) | [11.9](/filings/0001493152-25-011636.md) | not reported | [58.4](/filings/0001493152-25-021741.md) | [42.4](/filings/0001493152-26-037002.md) | [37.4](/filings/0001493152-26-022422.md) | [31.7](/filings/0001493152-26-037002.md) |
| Total assets | $m | [10.8](/filings/0001641172-25-000518.md) | [20.4](/filings/0001493152-24-018691.md) | [24.0](/filings/0001493152-24-032262.md) | [22.1](/filings/0001493152-24-043700.md) | [20.6](/filings/0001493152-26-013931.md) | [18.4](/filings/0001641172-25-009842.md) | [23.7](/filings/0001493152-25-011636.md) | not reported | [662](/filings/0001493152-25-021741.md) | [411](/filings/0001493152-26-037002.md) | [322](/filings/0001493152-26-022422.md) | [404](/filings/0001493152-26-037002.md) |
| Current liabilities | $m | [7.2](/filings/0001641172-25-000518.md) | [6.2](/filings/0001493152-24-018691.md) | [3.9](/filings/0001493152-24-032262.md) | [3.9](/filings/0001493152-24-043700.md) | [4.3](/filings/0001493152-26-013931.md) | [3.6](/filings/0001641172-25-009842.md) | [3.6](/filings/0001493152-25-011636.md) | not reported | [7.8](/filings/0001493152-25-021741.md) | [4.6](/filings/0001493152-26-037002.md) | [5.0](/filings/0001493152-26-022422.md) | [5.0](/filings/0001493152-26-037002.md) |
| Total liabilities | $m | [7.7](/filings/0001641172-25-000518.md) | [6.4](/filings/0001493152-24-018691.md) | [4.1](/filings/0001493152-24-032262.md) | [4.1](/filings/0001493152-24-043700.md) | [4.6](/filings/0001493152-26-013931.md) | [3.8](/filings/0001641172-25-009842.md) | [4.3](/filings/0001493152-25-011636.md) | not reported | [22.4](/filings/0001493152-25-021741.md) | [4.8](/filings/0001493152-26-037002.md) | [5.1](/filings/0001493152-26-022422.md) | [5.0](/filings/0001493152-26-037002.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [5.8](/filings/0001493152-24-012416.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.1](/filings/0001641172-25-000518.md) | [14.0](/filings/0001493152-24-018691.md) | [19.9](/filings/0001493152-24-032262.md) | [18.0](/filings/0001493152-24-043700.md) | [16.2](/filings/0001493152-26-013931.md) | [14.6](/filings/0001641172-25-009842.md) | [19.4](/filings/0001493152-25-011636.md) | not reported | [639](/filings/0001493152-25-021741.md) | [406](/filings/0001493152-26-037002.md) | [317](/filings/0001493152-26-022422.md) | [399](/filings/0001493152-26-037002.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,934) d](/filings/0001493152-24-043700.md) | [(2,123) d](/filings/0001641172-25-000518.md) | [(2,209)](/filings/0001641172-25-009842.md) | [(3,041) d](/filings/0001493152-25-011636.md) | [(1,651) d](/filings/0001493152-25-021741.md) | [(1,864) d](/filings/0001493152-26-013931.md) | [(1,070)](/filings/0001493152-26-022422.md) | [(2,286) d](/filings/0001493152-25-011636.md) | [(9,421) d](/filings/0001493152-25-021741.md) | [(7,992) d](/filings/0001493152-26-013931.md) | [(4,687)](/filings/0001493152-26-022422.md) | [(5,953) d](/filings/0001493152-26-037002.md) |
| Capital expenditure | $k | [17.0 d](/filings/0001493152-24-043700.md) | [10.0 d](/filings/0001641172-25-000518.md) | [23.0](/filings/0001641172-25-009842.md) | [54.0 d](/filings/0001493152-25-011636.md) | [105 d](/filings/0001493152-25-021741.md) | [160 d](/filings/0001493152-26-013931.md) | [66.0](/filings/0001493152-26-022422.md) | [2.0 d](/filings/0001493152-25-011636.md) | [14.0 d](/filings/0001493152-25-021741.md) | [6.0 d](/filings/0001493152-26-013931.md) | [9.0](/filings/0001493152-26-022422.md) | [(7.0) d](/filings/0001493152-26-037002.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [6,252 d](/filings/0001493152-26-013931.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.6](/filings/0001493152-23-041280.md) | [3.6](/filings/0001493152-24-018691.md) | [4.0](/filings/0001493152-24-032262.md) | [0.0](/filings/0001493152-24-043700.md) | [0.2](/filings/0001641172-25-009842.md) | [0.5](/filings/0001493152-25-011636.md) | [0.7](/filings/0001493152-25-021741.md) | [1.0](/filings/0001493152-26-022422.md) | [1.4](/filings/0001493152-26-037002.md) | [37.3](/filings/0001493152-25-021741.md) | [58.2](/filings/0001493152-26-022422.md) | [58.7](/filings/0001493152-26-037002.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,071,989 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-037002.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.